ARTICANZ - Beta (ver 0.91)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - target/GD2
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
target/GD2
3
trial(s) found.
NCT04221035
Radonc
Phase 3
Recruiting
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (
HR-NBL2
)
Busulfan
Carboplatin
Cisplatin
Cyclophosphamide
Dacarbazine
Dinutuximab
Doxorubicin
Etoposide
Ifosfamide
Irinotecan
Melphalan
Radiotherapy
Temozolomide
Thiotepa
Vincristine
alkylating agent
anthracycline
anti-GD2 monoclonal antibody
cancer therapy
cancer therapy,GD2-targeting
cytotoxic chemotherapy
immuno-oncology therapy,GD2-targeting
platinum-based antineoplastic agent
topoisomerase inhibitor
vinca alkaloid
+ anti-GD2 monoclonal antibody
Neuroblastoma
NSW
2031 - Randwick - Sydney Children's Hospital
2305 - New Lambton Heights - John Hunter Children's Hospital
2145 - Westmead - The Children's Hospital at Westmead (SUSPENDED)
VIC
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre
WA
6009 - Perth - Perth Children's Hospital (SUSPENDED)
ACTRN12622001514796
Advanced
Not Applicable
Recruiting
KARPOS
- A Phase 1, Single-Centre, Non-randomised, Open-labelled, Escalating Dose Study of Autologous GD2-Specific Chimeric Antigen Receptor-expressing Peripheral Blood T cells in Patients with Recurrent GD2-positive Glioblastoma Multiforme
Bevacizumab
CAR-T-cell therapy
CAR-T-cell therapy,GD2-targeting
Cyclophosphamide
Fludarabine
GD2-iCAR-PBT
Ifosfamide
alkylating agent
anti-VEGF monoclonal antibody
antimetabolite
autologous CAR-T-cell therapy
autologous CAR-T-cell therapy,GD2-targeting
cancer therapy
cancer therapy,GD2-targeting
cancer therapy,VEGF-targeting
cell therapy
cytotoxic chemotherapy
immuno-oncology therapy,VEGF-targeting
+ CAR-T-cell therapy,GD2-targeting
Glioblastoma
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
ACTRN12622000675729
Paed
Not Applicable
Recruiting
A Phase I Study of the Safety of Autologous GD2-Specific Chimeric Antigen Receptor-Expressing T Cells in Children with Diffuse Midline Glioma (
LEVI’S-CATCH
)
Bevacizumab
CAR-T-cell therapy
CAR-T-cell therapy,GD2-targeting
Cyclophosphamide
Fludarabine
GD2-iCAR-PBT
Radiotherapy
alkylating agent
anti-VEGF monoclonal antibody
antimetabolite
autologous CAR-T-cell therapy
autologous CAR-T-cell therapy,GD2-targeting
cancer therapy
cancer therapy,GD2-targeting
cancer therapy,VEGF-targeting
cell therapy
cytotoxic chemotherapy
immuno-oncology therapy,VEGF-targeting
+ CAR-T-cell therapy,GD2-targeting
Central nervous system cancer
Diffuse intrinsic pontine glioma
Diffuse midline glioma
High-grade glioma
NSW
2031 - Randwick - Prince of Wales Hospital
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (3)
Recruitment Country and State
NSW (2)
VIC (1)
SA (1)
Phase
Phase 3 (1)
Trial Type
Radonc (1)
Advanced (1)
Paed (1)
Cancer Therapy Class
GD2
100%
VEGF
67%
Facility
2031 - Randwick - Sydney Children's Hospital (1)
2145 - Westmead - The Children's Hospital at Westmead (1)
2305 - New Lambton Heights - John Hunter Children's Hospital (1)
3186 - Brighton - Cabrini Hospital Brighton Cancer Centre (1)
6009 - Perth - Perth Children's Hospital (1)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (1)
2031 - Randwick - Prince of Wales Hospital (1)
Cancer Type
Cancer
Neurological cancer
Solid tumour
Central nervous system cancer
Glioma
High-grade glioma
Malignant glioma
Neuroblastic tumour
Neuroblastoma
Peripheral nervous system tumour
Glioblastoma
Diffuse intrinsic pontine glioma
Diffuse midline glioma
H3K27M-mutant glioma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy